World Health Organization prioritizes Regeneron’s maftivimab for clinical trials targeting Bundibugyo ebolavirus as part of the global Ebola emergency response. Regeneron Pharmaceuticals (NasdaqGS:REG
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on REG
A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.
Cancer drug developer priced above range after demand reportedly reached about 10 times available shares.
The Cambridge, Massachusetts-based biotech priced 33.5 million shares at $20 each, topping the $625 million raised by Kailera Therapeutics in April
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion combined.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on May 28 that maftivim
View interactive chart, options flow, and AI analysis for REGN on Zorveq Finance.
Open REGN Chart & Analysis →